ResMed (NYSE: RMD) reported Q3 EPS of $0.71, in-line with the analyst estimate of $0.71. Revenue for the quarter came in at $514.2 million versus the consensus estimate of $519.87 million.

For earnings history and earnings-related data on ResMed (RMD) click here.